Free Trial
→ $2 Trillion Disappears Because of Fed's Secretive New Move (From Stansberry Research) (Ad)

BioLineRx Q4 2022 Earnings Report

BioLineRx logo
$0.10 +0.00 (+3.45%)
As of 04:00 PM Eastern
Earnings HistoryForecast

BioLineRx EPS Results

Actual EPS
-$0.09
Consensus EPS
-$0.14
Beat/Miss
Beat by +$0.05
One Year Ago EPS
N/A

BioLineRx Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

BioLineRx Announcement Details

Quarter
Q4 2022
Date
3/22/2023
Time
N/A

Conference Call Resources

Conference Call Audio

Powered by Quartr

BioLineRx Earnings Headlines

BioLineRx says current cash to provide runway through 2H26
January 21 at 9:36 PM | markets.businessinsider.com
BioLineRx announces strategic shift with licensing deals
January 21 at 11:34 AM | msn.com
$2 Trillion Disappears Because of Fed's Secretive New Move
$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being carried out by the Fed that has nothing to do with lowering or raising interest rates... but could soon have an enormous impact on your wealth.
January 21, 2025 | Stansberry Research (Ad)
BioLineRx Issues Letter to Shareholders
January 21 at 7:00 AM | prnewswire.com
BioLineRx (NASDAQ:BLRX) Now Covered by StockNews.com
January 20 at 2:43 AM | americanbankingnews.com
BioLineRx Shares Set to Reverse Split on Thursday, January 30th (NASDAQ:BLRX)
January 18 at 2:10 AM | americanbankingnews.com
See More BioLineRx Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like BioLineRx? Sign up for Earnings360's daily newsletter to receive timely earnings updates on BioLineRx and other key companies, straight to your email.

About BioLineRx

BioLineRx (NASDAQ:BLRX), a commercial stage biopharmaceutical company, develops and commercializes therapeutics for oncology and rare diseases. The company's pipeline includes APHEXDA (motixafortide), a peptide that is in Phase 1 clinical trial for the treatment of sickle cell disease, and Phase 2b clinical trial for the treatment of pancreatic cancer, as well as completed Phase 3 clinical trial for the treatment of multiple myeloma. It also develops BL-5010, a pen-like applicator containing an acidic aqueous solution for the non-surgical removal of skin lesions. BioLineRx Ltd. was incorporated in 2003 and is headquartered in Hevel Modi'in, Israel.

View BioLineRx Profile

More Earnings Resources from MarketBeat

Earnings Tools
Earnings By Country
Latest Articles